Long-term Immune Responses to Vaccination in HIV-Infected Patients: A Systematic Review and Meta-Analysis

Vaccine-induced antibodies may wane more quickly in persons living with human immunodeficiency virus (HIV) than in healthy individuals. We reviewed the literature on vaccines routinely recommended in HIV-infected patients to estimate how seroprotection decreases over time in those who initially resp...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2014-04, Vol.58 (8), p.1130-1139
Main Authors: Kernéis, Solen, Launay, Odile, Turbelin, Clément, Batteux, Frédéric, Hanslik, Thomas, Boëlle, Pierre-Yves
Format: Article
Language:English
Subjects:
Adolescent
Adult
AIDS vaccines
Antibodies
Biological and medical sciences
Child
Child, Preschool
Dosage
Hepatitis B vaccines
Highly active antiretroviral therapy
HIV
HIV Infections - immunology
HIV/AIDS
Human viral diseases
Humans
Immune system
Immunization
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infant
Infectious diseases
Japanese encephalitis vaccines
Medical sciences
Meta-analysis
Models, Statistical
Patients
Pneumococcal vaccines
Rubella vaccines
Systematic review
Time Factors
Vaccination - methods
Vaccines - administration & dosage
Vaccines - immunology
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Yellow fever vaccines
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccine-induced antibodies may wane more quickly in persons living with human immunodeficiency virus (HIV) than in healthy individuals. We reviewed the literature on vaccines routinely recommended in HIV-infected patients to estimate how seroprotection decreases over time in those who initially responded to immunization. For each study retrieved from the literature, the decrease of seroprotection was modeled with a log binomial generalized linear model, and data were pooled in a meta-analysis to provide estimates of seroprotection 2 and 5 years after the last vaccine administration. Our analyses confirmed that the duration of seroprotection was shorter in HIV-infected patients and that with current guidelines, a substantial proportion of patients would have lost protective antibodies before a booster was proposed. We therefore discuss the implications for the monitoring of antibody levels and timing of revaccination in these patients.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/cit937